Tracer library / [225Ac]Ac-DOTA-MSC3

[225Ac]Ac-DOTA-MSC3

Also written as [Ac-225]Ac-DOTA-MSC3

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Immune cell and immunotherapy imaging Preclinical only, no clinical indication yet Tumour hypoxia

What it is

Compound class: Monoclonal antibody (anti-CAIX antibody, DOTA-conjugated)
Target / mechanism: Carbonic anhydrase IX (CAIX), expressed on hypoxic tumor cells PMID 41799189
Clinical application: Hypoxic solid tumors treated with targeted alpha therapy, alone or in combination with immune checkpoint inhibitors PMID 41799189
Theranostic pair: [111In]DOTA-MSC3

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	81%	DOTA-MSC3	41799189 2026 Theranostics Details regarding antibody conjugation, radiolabeling and cell culture are described in the supplemental methods.

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-MSC3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41799189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41799189: 'Monoclonal anti-CAIX antibody DOTA-MSC3 was labeled with indium-111 (111In) or actinium-225 (225Ac)'. Stage set/updated at stage 23 from PMID 41799189: 'Overall, these results demonstrate first proof-of-concept of the potential of CAIX-TAT to treat hypoxic tumors by targeting CAIX-positive hypoxic tumor regions.'.